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Abstract
Neuronal nicotinic acetylcholine receptor (nAChR) genes (CHRNA5/CHRNA3/CHRNB4) have
been reproducibly associated with nicotine dependence, smoking behaviors, and lung cancer risk.
Of the few reports that have focused on early smoking behaviors, association results have been
mixed. This meta-analysis examines early smoking phenotypes and SNPs in the gene cluster to
determine: (1) whether the most robust association signal in this region (rs16969968) for other
smoking behaviors is also associated with early behaviors, and/or (2) if additional statistically
independent signals are important in early smoking. We focused on two phenotypes: age of
tobacco initiation (AOI) and age of first regular tobacco use (AOS). This study included 56,034
subjects (41 groups) spanning nine countries and evaluated five SNPs including rs1948,
rs16969968, rs578776, rs588765, and rs684513. Each dataset was analyzed using a centrally
generated script. Meta-analyses were conducted from summary statistics. AOS yielded significant
associations with SNPs rs578776 (beta = 0.02, P = 0.004), rs1948 (beta = 0.023, P = 0.018), and
rs684513 (beta = 0.032, P = 0.017), indicating protective effects. There were no significant
associations for the AOI phenotype. Importantly, rs16969968, the most replicated signal in this
region for nicotine dependence, cigarettes per day, and cotinine levels, was not associated with
AOI (P = 0.59) or AOS (P = 0.92). These results provide important insight into the complexity of
smoking behavior phenotypes, and suggest that association signals in the CHRNA5/A3/B4 gene
cluster affecting early smoking behaviors may be different from those affecting the mature
nicotine dependence phenotype.
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Introduction
Tobacco use usually begins during adolescence; over 90% of those who smoke more than
100 cigarettes become regular smokers and one-third of those adolescents who experiment
with tobacco go on to become nicotine dependent [Anthony et al., 1994; CDC, 2005;
Mayhew et al., 2000]. Symptoms of dependence in these youths may appear within weeks of
occasional tobacco use [DiFranza, 2008; DiFranza et al., 2000, 2002; Doubeni et al., 2010;
Escobedo et al., 1993; O’Loughlin et al., 2002a, 2002b], particularly loss of control over
their smoking [DiFranza et al., 2007; Scragg et al., 2008; Soteriades et al., 2011]. Early
initiation of tobacco use is also associated with an increased number of daily cigarettes
smoked in adulthood [Chen and Millar, 1998; D’Avanzo et al., 1994; Eisner et al., 2000;
Everett et al., 1999; Fernandez et al., 1999] and a decreased rate of smoking cessation
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[Breslau and Peterson, 1996; Chen and Millar, 1998; Eisner et al., 2000; Lando et al., 1999].
Age of smoking onset in women is a significant predictor of cessation during pregnancy; a
woman who initiates earlier is more likely to smoke while pregnant [Chen et al., 2006].
Individuals who initiate tobacco use early in life are also at greater risk for smoking-related
lung cancer, in part because this tissue type continues to develop into early adulthood [Hirao
et al., 2001; Wiencke and Kelsey, 2002; Wiencke et al., 1999]. In addition, smoking
accelerates the rate of cervical maturation and cell proliferation, therefore resulting in an
increased risk of cervical cancer [Hwang et al., 2009; Ma et al., 2011]. Given the long-term
health implications of early tobacco use, many studies have worked to identify and
understand the underlying genetic and environmental risk factors for early smoking
behaviors.
It is well established that genetic factors contribute to risk for tobacco initiation, quantity
smoked, nicotine dependence, and smoking persistence [Li et al., 2003; Rhee et al., 2003;
Rose et al., 2009; Schnoll et al., 2007]. Neuronal nicotinic acetylcholine receptor (nAChR)
subunit genes are among the top candidates for several smoking-related phenotypes because
a cluster of nicotinic receptor genes (CHRNA5/CHRNA3/CHRNB4) on chromosome 15q25
has been repeatedly associated with nicotine dependence, smoking behaviors, and lung
cancer [Amos et al., 2008; Berrettini et al., 2008; Broms et al., 2012; Furberg et al., 2010;
Greenbaum and Lerer, 2009; Hung et al., 2008; Liu et al., 2010; Rose, 2007; Saccone et al.,
2010a, 2007; Thorgeirsson et al., 2008; 2010]. This region also contains the nonsynonymous
risk variant rs16969968 G/A, that causes a functional amino acid change in the α5 subunit
protein (Asp398Asn); the Asparagine (Asn) allele decreases response to a nicotine agonist
[Bierut et al., 2008]. The high-risk α5 Asn 398 is associated with reduced Ca2+ permeability
and desensitizes faster than the wild type Aspartic acid (Asp) at 398 (α4β2)2 α5 [Kuryatov
et al., 2011]. In addition, Alpha5 knockout mice showed increased nicotine intake [Fowler et
al., 2011]. This variant accounts for 4% of the variance in the serum levels of the long-term
metabolite of nicotine, cotinine [Etter et al., 2009; Keskitalo et al., 2009]. In addition to this
well-characterized functional variant, there have been other robust associations within the
CHRNA5/CHRNA3/CHRNB4 gene cluster to smoking quantity. These were reported in three
genome-wide meta-analyses identifying SNPs in the cluster as top association signals with
the outcome of cigarettes smoked per day (CPD) [Furberg et al., 2010; Liu et al., 2010;
Thorgeirsson et al., 2010]. These reports support the prevailing view that smoking quantity/
frequency as a proxy for nicotine dependence is most consistently associated with SNPs at
the CHRNA5/CHRNA3/CHRNB4 locus. A fourth meta-analysis [Saccone et al., 2010a]
focused on four statistically distinct loci in the CHRNA5/CHRNA3/CHRNB4 cluster tagged
by SNPs rs16969968 (CHRNA5), rs578776 (CHRNA3), rs588765 (CHRNA5), and
rs12914008 (CHRNB4) [Saccone et al., 2009a]. SNPs rs16969968 and rs588765 were each
strongly associated with CPD in a joint model that adjusts for the effect of each, suggesting
independent effects; rs578776 is also associated with CPD, but its effect size is smaller after
adjustment for SNP rs16969968 in the association model [Saccone et al., 2010a].
Although the majority of the studies of CHRNA5/ CHRNA3/CHRNB4 variation and tobacco
have targeted smoking behaviors in adulthood, a few reports specifically focused on early
smoking behaviors. Weiss et al. found that a CHRNA5/CHRNA3/CHRNB4 haplotype
including SNPs rs16969968 and rs578776 was significantly associated with severity of
nicotine dependence among individuals who began daily smoking at or before age 16, but
not in those who began smoking after age 16 [Weiss et al., 2008]. Correlated SNPs rs1948
(CHRNB4) and rs8023462 (CHRNA3/CHRNB4) (r2 = 0.8) were found to be associated with
early age of tobacco initiation in two independent samples [Schlaepfer et al., 2008]. These
two SNPs are not in high linkage disequilibrium with any of the four loci mentioned above
(rs1696998 r2 = 0.32, rs578776 r2 = 0.09, rs588765 r2 = 0.56, and rs12914008 r2 = 0.02)
(1000 Genomes Pilot) 1 CEU [Abecasis et al., 2012]. A second study targeting age of
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tobacco initiation in a Korean sample found that SNPs rs6495308, rs11072768, and
rs951266 were significant for association [Li et al., 2010], but it is not clear whether in this
sample these SNPs are in high linkage disequilibrium with the four previously described
loci. Two genome-wide meta-analyses (with CPD as the primary phenotype) also included
age of tobacco initiation as an outcome and did not find any association that exceeded
genome-wide significance [Furberg et al., 2010; Thorgeirsson et al., 2010]. In another large
meta-analysis, age at onset of regular smoking modified the association between rs16969968
and CPD, with early onset of smoking being associated with a stronger gene–phenotype
association. In that analysis, no association was seen between dichotomized age of onset (at
age 16) and rs16969968 (P = 0.77) among 67,128 smokers [Hartz et al., 2012]. Thus, while
some reports have found evidence for association in this region with age of tobacco
initiation, others have not, and it has not been clear whether separate independent loci in
these genes may be associated with different phenotypes related to early smoking behavior.
The goal of the current study was to perform a meta-analysis specifically targeting early
smoking phenotypes and SNPs in the CHRNA5/CHRNA3/CHRNB4 gene cluster. These
analyses were undertaken to determine: (1) whether the most robust association signal in this
region shown for other smoking behaviors (rs16969968) is also seen for age of smoking
initiation and age of onset of regular smoking, and/or: (2) if additional statistically




A total of 56,034 subjects from 41 datasets spanning nine countries were included in a meta-
analysis. Sample sizes for each SNP and the two phenotypes differ (age of tobacco initiation
N ~ 12,662, age of onset of regular smoking N ~ 55,317) depending on which of the studies,
listed in Table 1, had contributed information. All but 11 of these datasets consisted of
unrelated ever-smokers of European descent. Details regarding individual study
characteristics are provided in supplementary Table S1. Eight (Dental Caries, VA-Twin,
NAG-FIN, NAG-OZALC, NTR1, NTR2, QIMR, and STR) were subsets of unrelated
subjects selected from family-based datasets. The Add Health, NYS-FS, and SMOFAM
datasets included family members of European descent. Informed consent was obtained
from all participants and was approved by the local institutional review boards. Inclusion
into this study required ever smokers to be assessed for (1) Age of tobacco initiation (AOI);
and/or (2) Age of onset of regular smoking (AOS). Mean AOI and AOS values are shown in
Table 1. Phrasing of AOI and AOS questions is provided in supplementary Table S1.
SNPs
SNP rs1948 was chosen due to a previously established association with AOI [Schlaepfer et
al., 2008]. Based on previous results [Saccone et al., 2010a; Saccone et al., 2009a], we also
included three statistically distinct nicotine dependence loci in the CHRNA5/A3/B4 gene
cluster: rs16969968, rs578776, and rs588765. If a group did not have genotype data for
SNPs rs16969968, rs578776, or rs588765 we chose a highly correlated (r2 > 0.8) SNP
proxy. Another option would have been to use imputed data. However, in that situation, it
would have been important for all imputation to be performed consistently between groups
which would have required some groups to reimpute specifically for this project. The
advantage of using an imputed SNP instead of a high-LD proxy for this study was not
compelling because the imputation quality of the SNP would need to be taken into account
as well. Thus, imputed SNPs were unlikely to add a significant amount of information to this
study and/or change the take home message. SNP proxies for applicable datasets are shown
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in Table 2. Information on r2 was obtained using Haploview HapMap II+III CEU [Barrett et
al., 2005] and the 1000 Genomes Pilot 1 CEU [Abecasis et al., 2012]. SNP rs684513 was
included due to associations with nicotine dependence [Winterer et al., 2010] and lung
cancer risk [Amos et al., 2010]; its r2 is less than 0.8 with rs16969968, rs578776, and
rs588765 in both Hapmap [Altshuler et al., 2010] and the 1000 genomes project (http://
www.1000genomes.org) CEU data [Abecasis et al., 2012]. Linkage disequilibrium (as
measured by r2) for all five loci is presented in Table 3. Allele frequencies for SNP proxies
and target SNPs in each dataset are given in Table 1.
Quality Control
Quality control procedures were carried out to ensure proper coding of variables across
studies. Specifically, this was carried out by examination of univariate and multivariate
distributions for phenotypic variables within each study, allele frequencies for SNPs, and
conformity with Hardy-Weinberg Equilibrium (HWE).
Statistical Analyses
Case/Control Data—To ensure consistent analyses across individual datasets, a unified
script was created using SAS (SAS Institute, Cary, NC) and R (http://www.r-project.org/).
These scripts were developed and distributed following protocols comparable to Saccone et
al. [Saccone et al., 2010a]. Briefly, participating groups held several planning conference
calls to decide on the analytical model and scripts were written through collaborative efforts
between SHS at the University of Colorado and SMH at Washington University in St. Louis.
Individual analyses were carried out by each participating group and summary results
returned to the coordinating group.
AOS and AOI phenotypes were normalized within each dataset. Z-scores were calculated to
correct for age and sex prior to analysis. Scripts were written to perform a linear regression
using AOS or AOI as the dependent variable and each SNP as the independent variable.
Each SNP was coded according to an additive model (0, 1, or 2 copies of the minor allele)
and each SNP was analyzed separately.
Family Data—PLINK [Purcell et al., 2007] was used to analyze the three datasets drawn
from families (Add Health, NYS-FS, and SMOFAM). The QFAM total association test (–
qfam-total) was used to conduct a family-based analysis that partitions the between family
variance and the within family variance [Fulker et al., 1999] and is similar to that
incorporated in the QTDT package [Abecasis et al., 2000]. This linear regression approach
was ideal for this study because beta values from each family study analysis could be
included.
In order to maintain uniformity in individual analyses, SHS compiled detailed instructions
and distributed these to the groups analyzing family data with information to Z-score AOS
or AOI in SAS (SAS Institute, Cary, NC) and R (http://www.r-project.org/), to code
additively with a consistent minor allele, and to perform the analyses in PLINK with the –
qfam-total option. Results were returned to SHS.
Meta-Analyses—Meta-analysis was carried out using the meta-analysis procedure in
PLINK [Purcell et al., 2007]. This procedure requires results files (for a quantitative trait)
with beta estimates, standard errors, and an optional P-value. PLINK meta-analysis output
includes a beta summary estimate, and a summary P-value for both random and fixed effects
models. The R package rmeta was used to create forest plots.
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In addition, the PLINK meta-analysis output provides a measure of heterogeneity with a P-
value for Cochrane’s Q statistic. This heterogeneity index in a meta-analysis refers to the
variation in outcomes (betas) between studies. The Q statistic is calculated as the weighted
sum of the squared differences between individual study effects (individual betas) and
pooled effects (summary beta) across studies. Q has a chi-squared distribution with number
of studies minus one degree of freedom.
A total of five SNPs and two phenotypes were examined, so the Bonferroni correction for
multiple testing would be 0.05/10 = 0.005. This threshold for significance is overly
conservative because of a correlation that exists between certain of these SNPs (rs684513/
rs578776 r2 = 0.6). However, the goal of this study was not to discover a novel association
but to disentangle the well-established association between these genes and tobacco
behaviors. Thus, the nominal P-values provided should be interpreted with this in mind.
Results
Descriptive
Allele frequencies were utilized to confirm correct coding of the minor allele for each locus
and are presented in Table 1. Frequencies were similar among individual datasets and also to
those of the target SNPs in the CEU population in HapMap. The mean AOI for the 15
contributing datasets was 14.4 years (range, 10.9–16.4). The mean AOS for the 39
contributing datasets was 18 years (range, 14.6–21.9).
Single SNP Analysis for AOI and AOS Phenotypes
Tables 4 and 5 show PLINK meta-analysis results for each single locus and the AOI and
AOS quantitative phenotypes. Results were nearly identical for both the fixed effects and
random effects models. Table 4 presents results of AOI analysis where column one shows
the SNP/Locus and columns two and three are the number of contributing datasets and the
number of subjects with genotypic and phenotypic information at that SNP/Locus. Columns
four and five show the summary beta and P-value, respectively. Column six is the P-value
for the Cochrane’s Q statistic. There were no significant associations for AOI at any of the
five loci.
Table 5 shows the corresponding results of AOS meta-analyses. Locus rs578776 was
significantly associated with AOS (beta = 0.02, nominal P = 0.004, adjusted P = 0.04).
Figure 1A shows the meta-analysis forest plot for the association between rs578776 with a
phenotype of AOI while Figure 1B shows these results for AOS. Although the rs578776
locus was not significantly associated with AOI, both betas were 0.02 and suggest that for
AOS, the minor allele confers a protective effect because it is associated with a later age of
smoking onset. In addition, SNPs rs1948 and rs684513 were associated with AOS (rs1948
beta = 0.023, P = 0.018; rs684513 beta = 0.032, P = 0.017). Figure 2A and B show meta-
analysis forest plots for rs1948 with AOI and AOS, respectively. Figure 3A and B show
forest plots for rs684513 AOI and AOS, respectively.
Cochrane’s Q statistic P-values (column six of Tables 4 and 5) indicate that there was one
SNP/loci (rs588765 AOS only) showing modest heterogeneity.
Discussion
This meta-analysis was designed to examine the relationship of SNPs in the CHRNA5/
CHRNA3/CHRNB4 gene cluster with early smoking behaviors including AOI and AOS.
Genetic variation in this genomic region shows robust association to nicotine dependence
and tobacco use behaviors in adult samples [Furberg et al., 2010; Liu et al., 2010; Saccone et
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al., 2010a; Thorgeirsson et al., 2010]. Although previous studies examining association with
tobacco initiation [Furberg et al., 2010; Thorgeirsson et al., 2010] and first regular use have
been inconclusive, most have not found association with the locus including SNP
rs16969968 [Furberg et al., 2010; Hartz et al., 2012; Thorgeirsson et al., 2010]. We
hypothesized that a possible explanation for conflicting reports may be related to the
multiple independent loci in this region [Saccone et al., 2009a; Saccone et al., 2010b], if
different loci contribute to different smoking-related phenotypes. This analysis expands on
previous work by examining two additional SNPs (rs1948 and rs684513) based on previous
associations with smoking-related phenotypes [Amos et al., 2010; Schlaepfer et al., 2008;
Winterer et al., 2010], in addition to three statistically independent nicotine dependence loci
in the CHRNA5/A3/B4 gene cluster: rs16969968, rs578776, and rs588765.
Results revealed evidence for association between AOS and three of the five target SNPs.
Importantly, AOS shows no association with rs16969968, which is strongly and
reproducibly associated with nicotine dependence, smoking quantity, and cotinine levels
[Furberg et al., 2010; Greenbaum and Lerer 2009; Keskitalo et al., 2009; Saccone et al.,
2010b; Saccone et al., 2007; Thorgeirsson et al., 2010]. This is consistent with previous
reports [Broms et al., 2012; Ducci et al., 2011; Furberg et al., 2010; Thorgeirsson et al.,
2010; Weiss et al., 2008]. One explanation put forward for the lack of findings with tobacco
initiation and rs16969968 is a report by Hong et al where the “risk” allele (A) predicts a
defect in a dorsal anterior cingulate-ventral striatum/extended amygdala circuit whose
weakness predicts addiction severity [Hong et al., 2011]. One could also reason that
rs16969968 is not associated with initiation and instead more strongly related to craving and
ability to quit due to the action of CHRNA5 to alter output of deep cortical layers [Picciotto
and Kenny, 2012].
In the current report, the strongest evidence for association with AOS was detected with
SNP rs578776 (P = 0.004). There was also evidence for association between SNPs rs1948
(beta = 0.023, P = 0.018) and rs684513 (beta = 0.032, P = 0.017) and AOS. Similar to
rs578776, the betas for these SNPs were positive, signifying that having more copies of the
minor alleles is associated with a later age of smoking onset. Results with rs578776 and
rs684513 are in agreement with a previous study [Broms et al., 2012], where there was
evidence for association of age of onset of smoking (AOS) and the Locus 2 signal
(rs578776) and rs684513. In addition, significance with rs1948 in this report is supported by
previous findings of significant association with “smoking at age 14” and suggestive
evidence with age of onset of smoking [Broms et al., 2012].
In contrast to the AOS findings, there was no evidence for association between AOI and any
of the SNPs examined in the CHRNA5/A3/B4 cluster. It might be intuitively expected that
AOI and AOS would be highly correlated and that the associations with risk SNPs would
not vary between them greatly even though there are differences in statistical power between
AOI and AOS due to sample size. However, the correlations between AOI and AOS among
the samples where both measures are available are actually rather low (ranging from 0.20–
0.65, data not shown). There is additional support for the hypothesis that a low correlation
exists between these two phenotypes. Breslau et al. (1993) showed the lag time from first
cigarette to daily smoking onset was significantly longer in those who initiated <14 years of
age relative to those initiating ≥17 years of age. A social explanation was proposed for these
findings in that early initiators were said to face a nonpermissive environment (e.g.
availability, community norms, adult supervision, etc.) [Breslau et al., 1993]. In addition, we
performed an ad hoc exploratory analysis to determine whether there were any trends with
the five loci and the delta between AOI and AOS. Utilizing a subset of samples with both
phenotypes available (Add Health, CADD, COGA, COGEND, NYS-FS, YFS), we found no
evidence for association between the AOI–AOS time differential and any of the loci used for
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this study (data not shown). The similarities and differences in results across SNPs for the
two phenotypes are interesting also to consider in the context of work finding an association
between externalizing behaviors and rs8040868, which is a locus not well-tagged by the
SNPs investigated here [Stephens et al., 2012]. It is possible that some of the differences
between AOI and AOS results are related to more general underlying behaviors, such as
novelty-seeking and conduct disorder. Future studies aimed at disentangling possible unique
genetic contributions to these phenotypes are merited. An alternative explanation for these
findings could be biological. Age at initiation is related to behavioral traits such as Attention
Deficit Hyperactivity Disorder (ADHD), Conduct Disorder (CD), Oppositional Deviant
Disorder (ODD), delinquency, and criminal behavior [Armstrong and Costello, 2002; Flory
et al., 2003; Han et al., 1999; Krueger et al., 2002; McGue and Iacono, 2008; McGue et al.,
2001; Sihvola et al., 2011; Tarter et al., 2003; Young et al., 2000], while the time from
initiation to regular smoking could be related to individual differences in neuroadaptation to
nicotine and other psychoactive components of tobacco. Thus, it is reasonable to propose
that nicotinic receptor properties are related to the neuroadaptation process and consequently
to CHRN gene polymorphisms.
These findings corroborate and strengthen certain previous reports. Rs578776 (CHRNA3)
has been previously associated with nicotine dependence in subjects of European ancestry
[Saccone et al., 2009a, 2009b, 2010b; Weiss et al., 2008] and heavy smoking [Stevens et al.,
2008] with the minor allele (T) acting in a protective manner against nicotine dependence.
Our results also support the protective effect of the minor allele where a positive beta (0.02)
indicated a later age of first regular smoking among individuals with 1 or 2 copies of the T
allele. However, the SNP is not known to be functional, so the basis for the association
needs to be investigated further. SNP rs1948 (CHRNB4) has previously been associated with
tobacco and alcohol age of initiation in the CADD sample and NYS-FS samples [Schlaepfer
et al., 2008], but few other studies have focused on this locus. SNP rs1948 was recently
associated with the tolerance factor of the Nicotine Dependence Syndrome Scale (NDSS) (P
= 0.0071) [Broms et al., 2012] and SNP rs684513 (major allele) has been previously
associated with nicotine dependence [Winterer et al., 2010] and lung cancer risk [Amos et
al., 2010]. Lori et al found an association with FTND of this CHRNA5 SNP [Lori et al.,
2011]. These meta-analysis results support previous findings showing a protective effect of
the minor allele for AOS (P = 0.015, beta = 0.034).
The PLINK meta-option reports the Cochrane’s Q statistic as a measure of heterogeneity for
each SNP. One significant heterogeneity P-value was obtained for SNP rs588765 (P = 0.01)
in the AOS analysis only. It is unlikely this heterogeneity can be accounted for by
differences in phenotype assessment between studies because this would be predicted to
result in significant heterogeneity for all loci in the AOS analysis. Large differences in allele
frequencies between groups could also produce heterogeneity. Examination of allele
frequencies for all participating groups suggests one outlier (NTR1 T allele frequency is 0.9)
within this SNP/locus. In order to determine whether this sample population was driving the
significant Q statistic for rs588765 and AOS, the meta-analysis was performed excluding
this sample. Results for AOS were similar and the Q statistic P-value was identical (beta =
−0.004, P = 0.281, Q P-value = 0.01) suggesting the NTR1 rs588765 T allele frequency is
not the cause of observed heterogeneity at this locus. Furthermore, results from a random
effects model (automatically generated by PLINK) were nearly identical for rs588765 (fixed
effects beta = −0.009, P = 0.297, random effects beta = −0.005, P = 0.402). Thus,
heterogeneity across samples is unlikely to be driving the association results for AOS with
these two SNPs.
There are several limitations to this study. First, given the involvement of many groups
across several countries and use of data collected for other purposes, methods for
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assessments were not consistent across all studies. The phrasing of questions differed across
sites, and although an attempt was made to harmonize the phenotypes it would have been
ideal to use the same tools and questions. Second, some groups did not have both AOI and
AOS data, so direct comparison of results is incomplete because power to detect an
association differs. Third, the exact same SNPs were not available for all groups, so we
relied on the use of proxy SNPs based on the current HapMap data. It is possible that some
of the SNPs used as proxies are not as well correlated with the target SNP signal as we
believe, but given the large datasets now available, this is unlikely for most of the targets.
This study also features several strengths. First, this study was built on strong existing
support for an important role of this gene cluster, enabling the efforts to be focused on
characterizing the associations in the region. Second, this project began with multiple
discussions by all participants about the goals for the study, after which a specific analytical
plan was developed to test carefully defined hypotheses, thereby minimizing multiple
testing. Third, the sample sizes are substantial and therefore have allowed us to separate the
effects of unique loci in a manner not otherwise possible.
The most significant finding (rs578776) has been associated with nicotine dependence in
multiple independent samples and the minor allele confers a protective effect. Results of this
meta-analysis suggest the protective effect imparted by the minor allele may influence early
smoking behaviors, resulting in a decreased risk of nicotine dependence later in life. Perhaps
even more interesting is the fact that there was absolutely no evidence at the most highly
replicated locus for smoking heaviness (rs16969968), which has been shown to confer a
functional effect on receptor function [Bierut et al., 2008; Fowler et al., 2011; Kuryatov et
al., 2011]. This is the third study to report nonsignificance for age of initiation or age of
onset of smoking at the rs16969968 [Furberg et al., 2010; Hartz et al., 2012; Thorgeirsson et
al., 2010]. This work emphasizes the fact that early smoking behaviors are related to, but
different from nicotine dependence. It also demonstrates the value in pursuing multiple
SNPs in a region where one SNP has been definitively associated with behavior and has
concomitant evidence for molecular function. It is likely that other genes found to be
associated with complex behaviors will harbor multiple functional variants, which may be
involved in different aspects in the development of the disorder. For example, the most
significantly associated SNP in this study (rs578776) represents a possible target for early
intervention, while SNP rs16969968 may be a more effective target for later treatment.
Taken as a whole, these results underscore the complexity of smoking behavior phenotypes,
and suggest different genetic signals in this region may contribute to different stages of
tobacco use and dependence.
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(A) Meta-analysis forest plot for rs578776 age of tobacco (AOI) initiation showing the
individual betas (for each study), summary beta, individual number of subjects (n), summary
n, and a summary P-value. Individual and summary betas are for the rs578776 T allele. (B)
Meta-analysis forest plot for rs578776 age of first regular tobacco use (AOS) showing the
individual betas (for each study), summary beta, individual number of subjects (n), summary
n, and a summary P-value. Individual and summary betas are for the rs578776 T allele.
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(A) Meta-analysis forest plot for rs1948 age of tobacco initiation (AOI) showing the
individual betas (for each study), summary beta, individual number of subjects (n), summary
n, and a summary P-value. Individual and summary betas are for the rs1948 A allele. (B)
Meta-analysis forest plot for rs1948 age of first regular tobacco use (AOS) showing the
individual betas (for each study), summary beta, individual number of subjects (n), summary
n, and a summary P-value. Individual and summary betas are for the rs1948 A allele.
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(A) Meta-analysis forest plot for rs684513 age of tobacco initiation (AOI) showing the
individual betas (for each study), summary beta, individual number of subjects (n), summary
n, and a summary P-value. Individual and summary betas are for the rs684513 G allele. (B)
Meta-analysis forest plot for rs684513 age of first regular tobacco use (AOS) showing the
individual betas (for each study), summary beta, individual number of subjects (n), summary
n, and a summary P-value. Individual and summary betas are for the rs684513 G allele.
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Table 2
Summary of SNP proxies for participating groups. Column 1 lists the acronym for each group, defined in the
Supplementary Information (Dataset Descriptions). Columns 2–4 show the SNP proxies utilized by each
group for rs16969968, rs578776, and rs588765 respectively. If a space is blank then the group genotyped the
SNP of interest directly. A “–” indicates the group neither genotyped the SNP of interest directly, nor had an
available proxy
















MDACC LCA rs1051730 rs6495309 rs6495306
MDACC Melanoma rs6495306
MUC12 cases rs1051730 rs6495309 rs6495306
MUC12 controls rs1051730 rs6495309 rs6495306
MUCMD cases rs680244
MUCMD controls rs680244
NAG OZALC rs1051730 rs6495309 rs680244
NAG FIN rs1051730 rs6495306
NESDA rs11637635
NFBC1966 rs1051730 rs6495309 rs6495306
NHS BRCA rs1051730 rs6495306
NHS CHD rs951266 rs6495306 rs938682
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Table 3
Linkage Disequilibrium values (as measured by r2) utilized for the meta-analysis and taken from the 1000
genomes project Pilot 1 http://www.1000genomes.org/




rs1948 0.32 0.09 0.56
rs684513 0.1 0.61 0.1 0.06
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